Urine ddPCR and Electrophoresis for Canine UC Variant Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for diagnosing canine urothelial carcinoma (UC) are invasive, expensive, and often inconclusive due to limited sample availability and variable cell appearances, leading to delayed diagnosis and inadequate understanding of molecular events in BRAF V595E-negative cases, which may represent distinct clinical subtypes requiring alternative therapeutic targets.
Innovation Solution
Development of a urine-based droplet digital PCR (ddPCR) assay for detecting BRAF V595E mutations and a capillary electrophoresis assay for identifying deletions in BRAF exon 12 and MAP2K1 exons 2/3, combined with whole exome sequencing, to classify UC cases and tailor treatment strategies based on specific genetic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cytological methods are used for diagnosis, then the diagnostic process is simple, but the sensitivity and reliability are low leading to delayed diagnosis
Solution Approach 1:
The patent replaces conventional mechanical cytological examination with molecular biology-based PCR detection methods. Specifically, it uses droplet digital PCR (ddPCR) and capillary electrophoresis to detect BRAF V595E mutations and other genetic markers in urine samples, substituting the mechanical visual inspection system with a molecular detection system that provides higher sensitivity and reliability while maintaining efficiency
Solution Approach 2:
The patent introduces molecular markers (BRAF V595E mutation, MAP2K1 mutations, and other genetic markers) as intermediaries to bridge the gap between simple urine collection and reliable diagnosis. These molecular markers serve as mediators that enable accurate detection of urothelial carcinoma without requiring complex tissue biopsy procedures, thus improving diagnostic reliability while avoiding time loss
2Measurement precision
If tissue biopsy is performed for definitive diagnosis, then diagnostic accuracy is high, but the procedure is invasive and expensive
Solution Approach 1:
The patent extracts the essential diagnostic information (molecular markers of urothelial carcinoma) from the complex tissue biopsy procedure by detecting BRAF V595E mutations and other genetic markers directly in urine samples. This extraction approach isolates the critical diagnostic function from the invasive biopsy procedure, achieving high diagnostic accuracy without the harmful effects of tissue sampling
Solution Approach 2:
The patent creates a molecular copy of the diagnostic information found in tissue biopsies by detecting the same BRAF V595E mutations and other genetic markers present in tumor cells through urine-based PCR assays. This molecular copying allows definitive diagnosis to be obtained from non-invasive urine samples rather than requiring actual tissue extraction
3Adaptability or versatility
If only BRAF V595E mutation testing is performed, then the assay is simple, but it misses BRAF V595E-negative cases that may represent distinct clinical subtypes
Solution Approach 1:
The patent makes the diagnostic system universal by expanding it to detect multiple types of molecular markers beyond just BRAF V595E mutations. It incorporates detection of MAP2K1 mutations, other BRAF mutations, and additional genetic markers, enabling the same urine-based PCR platform to serve multiple diagnostic functions and cover diverse clinical subtypes of urothelial carcinoma
Solution Approach 2:
The patent segments the molecular detection process into multiple targeted assays, each detecting specific genetic markers (BRAF V595E, MAP2K1 mutations, and other markers). This segmentation allows the complex multi-marker detection to be organized into manageable, modular PCR assays that can be performed systematically, reducing the perceived complexity while expanding detection coverage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assays provide high sensitivity and specificity for UC detection and enable personalized treatment approaches by identifying alternative therapeutic targets in BRAF V595E-negative cases, potentially improving survival rates and treatment efficacy.
Implementation Method 1
droplet digital PCR (ddPCR) analysis for identification of exfoliated tumor cells bearing a specific activating mutation in exon 15 of the BRAF gene
Implementation Method 2
a capillary electrophoresis assay for identifying deletions in BRAF exon 12 and MAP2K1 exons 2/3
Data Source
AI summary
Provided are methods for detecting urogenital malignancies in dogs. In some embodiments, the methods include identifying a deletion or single nucleotide substitution within a BRAF gene and/or within a MAP2K1 gene present in or isolated from a biological sample from a. dog, wherein the presence of the deletion or single nucleotide substitution within the BRAF gene and/or within the MAP2K1 gene detects a urogenital malignancy, optionally transitional cell carcinoma/urothelial carcinoma, in the dog. In some embodiments, the deletion is within exon 12 of BRAF gene, optionally within the amino acid sequence KMLNVTAPTPQQL (SEQ ID NO: 3), and/or in within exon 2 or 3 of a M.AP2K1 gene, optionally within the amino acid sequence FLTQKQKVGE (SEQ ID NO: 4).